Celiac disease: Promising biomarkers for follow-up

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F23%3AE0110583" target="_blank" >RIV/00843989:_____/23:E0110583 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/23:00132727 RIV/61988987:17110/23:A2402NYA RIV/61989592:15110/23:73621821 RIV/65269705:_____/23:00078874 a 2 dalších

Výsledek na webu

<a href="https://jgld.ro/jgld/index.php/jgld/article/view/4926/1999" target="_blank" >https://jgld.ro/jgld/index.php/jgld/article/view/4926/1999</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.15403/jgld-4926" target="_blank" >10.15403/jgld-4926</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Celiac disease: Promising biomarkers for follow-up

Popis výsledku v původním jazyce

Celiac disease is a common gastroenterological illness. Current diagnostics of the disease are based on serological markers and histology of duodenal biopsies. Hitherto, a strict gluten-free diet is the only effective treatment and is necessary for good control of the disease. Serological tests in current use have very high specificity and sensitivity for diagnostics, but in follow-up they have some limitations. Their levels do not accurately reflect mucosal healing, and they are unable to detect minimal transgressions in the diet. This problem is significant in patients with IgA deficiency, and there exist no robust follow-up tools for monitoring these patients' adherence to treatment. For their follow-up, we currently use IgG-based tests, and these antibodies persist for a long time even when a patient has stopped consuming gluten. More accurate and specific biomarkers are definitely needed. Adherence to a gluten-free diet is essential not only for intestinal mucosa healing and alleviation of symptoms but also for preventing complications associated with celiac disease. Here, we summarize current evidence regarding noninvasive biomarkers potentially useful for follow-up not only of patients with IgA deficiency but for all patients with celiac disease. We describe several very promising biomarkers with potential to be part of clinical practice in the near future.

Název v anglickém jazyce

Celiac disease: Promising biomarkers for follow-up

Popis výsledku anglicky

Celiac disease is a common gastroenterological illness. Current diagnostics of the disease are based on serological markers and histology of duodenal biopsies. Hitherto, a strict gluten-free diet is the only effective treatment and is necessary for good control of the disease. Serological tests in current use have very high specificity and sensitivity for diagnostics, but in follow-up they have some limitations. Their levels do not accurately reflect mucosal healing, and they are unable to detect minimal transgressions in the diet. This problem is significant in patients with IgA deficiency, and there exist no robust follow-up tools for monitoring these patients' adherence to treatment. For their follow-up, we currently use IgG-based tests, and these antibodies persist for a long time even when a patient has stopped consuming gluten. More accurate and specific biomarkers are definitely needed. Adherence to a gluten-free diet is essential not only for intestinal mucosa healing and alleviation of symptoms but also for preventing complications associated with celiac disease. Here, we summarize current evidence regarding noninvasive biomarkers potentially useful for follow-up not only of patients with IgA deficiency but for all patients with celiac disease. We describe several very promising biomarkers with potential to be part of clinical practice in the near future.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30219 - Gastroenterology and hepatology

Projekt

<a href="/cs/project/NU23-06-00553" target="_blank" >NU23-06-00553: Optimalizace monitoringu celiakie a nové možnosti její prevence</a><br>

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of gastrointestinal and liver diseases

ISSN

1841-8724

e-ISSN

1842-1121

Svazek periodika

32

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

RO - Rumunsko

Počet stran výsledku

9

Strana od-do

536-544

Kód UT WoS článku

001158173500017

EID výsledku v databázi Scopus

2-s2.0-85180874390